New Insights on ATTR-CM Detection, Tracers, Diagnosis, and Treatment

ASNC’s just-published Imaging Insights newsletter focuses on the evolving diagnostic and therapeutic landscape of transthyretin amyloid cardiomyopathy. Check out these 3 features:

2025 Mario Verani Memorial Lecturer Prem Soman, MD, PhD, MASNC, shares ideas on how to enhance ATTR-CM detection.

Looking for Cardiac Amyloidosis in Your Community: 3 Approaches That Work for Busy Practices

Despite breathtaking advancements in the diagnosis and treatment of cardiac amyloidosis, a major hurdle for clinical practices is early detection – finding the individuals who should be tested for cardiac amyloidosis so they can get started on their journey toward effective management as soon as possible. Try these approaches for accelerating early detection in your community.

Early Diagnosis and Treatment Put Age-Expected Longevity within Reach for Patients with ATTR-CM

Sponsored by Alnylam Pharmaceuticals

Striking findings! Brett W. Sperry, MD, FASNC, compared survival data from HELIOS-B alongside U.S. actuarial data.

The field of cardiac amyloidosis has progressed at remarkable speed, but there are still many unanswered questions, among them how clinicians could evaluate a patient’s response to therapy and then, based on the evaluation, adjust treatment. A new analysis is hinting at how new therapies are bringing mortality rates for ATTR-CM patients in line with those of the U.S. general population.

Pan-Amyloid Tracers Coming! How Will They Change the Landscape?

Jonathan S. Wall, PhD, provides perspective on the potential of two new radiotracers for imaging amyloid.

In studies presented at ASNC2025, two investigational radiotracers – the PET/CT radiotracer (124I) evuzamitide and the SPECT agent 99mTc-p5+14 (AT-05) – demonstrated high levels of sensitivity and specificity for detecting cardiac amyloid in ATTR and AL patients. How might these tracers transform the cardiac amyloidosis landscape? ASNC asked the biochemist whose team invented the peptide on which both tracers are built.

Explore Imaging Insights